News
CFRXQ
0.015
-3.23%
-0.001
Weekly Report: what happened at CFRXQ last week (0708-0712)?
Weekly Report · 9h ago
Weekly Report: what happened at CFRXQ last week (0701-0705)?
Weekly Report · 07/08 11:08
Weekly Report: what happened at CFRXQ last week (0624-0628)?
Weekly Report · 07/01 11:08
Weekly Report: what happened at CFRXQ last week (0617-0621)?
Weekly Report · 06/24 11:16
Weekly Report: what happened at CFRXQ last week (0610-0614)?
Weekly Report · 06/17 11:07
Weekly Report: what happened at CFRXQ last week (0603-0607)?
Weekly Report · 06/10 11:09
Weekly Report: what happened at CFRXQ last week (0527-0531)?
Weekly Report · 06/03 11:12
Weekly Report: what happened at CFRXQ last week (0520-0524)?
Weekly Report · 05/27 11:17
Weekly Report: what happened at CFRXQ last week (0513-0517)?
Weekly Report · 05/20 11:10
Weekly Report: what happened at CFRXQ last week (0506-0510)?
Weekly Report · 05/13 11:20
Weekly Report: what happened at CFRXQ last week (0429-0503)?
Weekly Report · 05/06 11:27
Weekly Report: what happened at CFRXQ last week (0422-0426)?
Weekly Report · 04/29 11:35
Weekly Report: what happened at CFRXQ last week (0415-0419)?
Weekly Report · 04/22 11:23
Weekly Report: what happened at CFRXQ last week (0408-0412)?
Weekly Report · 04/15 11:14
Weekly Report: what happened at CFRXQ last week (0401-0405)?
Weekly Report · 04/08 11:19
Weekly Report: what happened at CFRXQ last week (0325-0329)?
Weekly Report · 04/01 11:17
Weekly Report: what happened at CFRXQ last week (0318-0322)?
Weekly Report · 03/25 11:20
Weekly Report: what happened at CFRXQ last week (0311-0315)?
Weekly Report · 03/18 11:18
Biotech bankruptcies hit a record despite sector’s recovery
Healthcare Biotech bankruptcies hit a record despite sector’s recovery. More biotech firms filed for Chapter 11 bankruptcy than any other year since 2010. In 2023, 18 biotech companies petitioned for court-mediated protection, compared to eight in 2022. The record number of biotech bankruptcies contrasts with the industry's recent gains.
Seeking Alpha · 03/14 18:54
Weekly Report: what happened at CFRXQ last week (0304-0308)?
Weekly Report · 03/11 11:14
More
Webull provides a variety of real-time CFRXQ stock news. You can receive the latest news about Contrafect Corp through multiple platforms. This information may help you make smarter investment decisions.
About CFRXQ
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its CF-301 is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.